Sugi Predict

Sugi Predict / Compounds / SCHEMBL865718

SCHEMBL865718

SCHEMBL865718

CCCCCN(CCCC)C(C)C

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ DNM1 Q05193 5/20 0.43
▸ TSHR P16473 1/20 0.37
▸ THRB P10828 1/20 0.37
▸ OPRM1 P35372 1/20 0.36
▸ CA12 O43570 1/20 0.34
▸ CA1 P00915 1/20 0.34
▸ CA2 P00918 1/20 0.34
▸ CA9 Q16790 1/20 0.34
▸ TP53 P04637 1/20 0.33
▸ MMP1 P03956 1/20 0.33
▸ MMP2 P08253 1/20 0.33
▸ MMP3 P08254 1/20 0.33
▸ MMP8 P22894 1/20 0.33
▸ GGPS1 O95749 3/20 0.32
▸ GBA1 P04062 1/20 0.32
▸ PLA2G1B P04054 1/20 0.32
▸ PLA2G2A P14555 1/20 0.32
▸ TRPM8 Q7Z2W7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11252414 0.97 DNM1 (0.48) DNM1TSHRTHRBOPRM1CA12
SCHEMBL10379743 0.97 DNM1 (0.48) DNM1TSHRTHRBOPRM1CA12
SCHEMBL3309868 0.97 DNM1 (0.46) DNM1TSHRTHRBOPRM1CA12
SCHEMBL9396454 0.94 DNM1 (0.50) DNM1TSHRTHRBOPRM1CA12
SCHEMBL9395742 0.94 DNM1 (0.50) DNM1TSHRTHRBOPRM1CA12
SCHEMBL10379464 0.94 DNM1 (0.50) DNM1TSHRTHRBOPRM1CA12
SCHEMBL611689 0.94 DNM1 (0.50) DNM1TSHRTHRBOPRM1CA12
SCHEMBL9815759 0.94 DNM1 (0.50) DNM1TSHRTHRBOPRM1CA12
SCHEMBL3365357 0.94 DNM1 (0.50) DNM1TSHRTHRBOPRM1CA12
SCHEMBL5926068 0.94 DNM1 (0.50) DNM1TSHRTHRBOPRM1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230302138-A1 COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS RECODE THERAPEUTICS, INC. 2023-09-28 — — US disclosed
US-10980889-B1 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors Revolution Medicines, Inc. (US) 2021-04-20 — — US disclosed
CN-110233290-A Nonaqueous electrolyte solution and nonaqueous electrolyte secondary battery using same 三菱化学株式会社 2019-09-13 — — CN disclosed
CN-104966849-B Nonaqueous electrolyte solution and nonaqueous electrolyte secondary battery using same 三菱化学株式会社 2019-06-07 — — CN disclosed
US-8143282-B2 Heterocyclic compounds S*BIO PTE LTD. (SG) 2012-03-27 — — US disclosed
US-20090048300-A1 Heterocyclic Compounds S*BIO PTE LTD. (SG) 2009-02-19 — — US disclosed
US-4557838-A NITROGEN COMPOUND, ACETYLENIC ALCOHOL AND DIBUTYLTHIOUREA AIR PRODUCTS AND CHEMICALS, INC. (US) 1985-12-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10980889-B1 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors MTOR, RICTOR, RPTOR DNM1 1171/4885TSHR 3817/4885THRB 3468/4885
US-20230302138-A1 COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS CHMP4B, LIPA, NPC1L1 DNM1 307/4885TSHR 2262/4885THRB 2609/4885
US-20090048300-A1 Heterocyclic Compounds HDAC1, HDAC3, HDAC11 DNM1 2396/4885TSHR 3681/4885THRB 3640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.